Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
14 evidence topics · 17 sources
Barzolvolimab phase 2: efficacy at Week 12 and Week 52 by baseline total IgE
Barzolvolimab phase 2: Week 12 response with and without prior omalizumab
Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants
| Population and arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
|---|---|---|
| Overall, placebo | “9.3%” | “12.6%” |
| Overall, 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| Overall, 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |
| Omalizumab-refractory, placebo | “9.3%” | “15.1%” |
| Omalizumab-refractory, 150 mg Q4W | “55.3% (p<.00001)” | “41.7% (p=.0089)” |
| Omalizumab-refractory, 300 mg Q8W | “44.3% (p=.00017)” | “46.4% (p=.0036)” |
Barzolvolimab phase 2: efficacy by baseline serum tryptase
International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines
“In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of predictors of response to antihistamines, omalizumab, and cyclosporine
“A systematic search was performed by two independent researchers using the MEDLINE/PubMed database with specific keywords and 73 studies included in the review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“High disease activity, high levels of C-reactive protein and D-dimer are robust predictors for a poor or no response to sgAHs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Poor or no response to omalizumab is robustly predicted by low serum levels of total IgE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A good response to cyclosporine is robustly predicted by a positive basophil histamine release assay, whereas low total IgE is an emerging predictor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab: response by baseline total IgE and its change after 4 weeks
“Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune endotype: low total IgE and poor response to antihistamines and omalizumab
Dupilumab: response by baseline total IgE in omalizumab-naive participants
“Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dupilumab is an effective treatment in H1-antihistamine (H1-AH)-resistant, omalizumab-naïve patients with CSU, regardless of their baseline serum total IgE levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dupilumab: label statements on baseline IgE and on anti-IgE inadequate responders
Remibrutinib and dupilumab by prior biologic or omalizumab exposure
“Dupilumab, a monoclonal antibody that blocks IL-4Ra, significantly reduced urticaria activity in omalizumab-naive patients and showed smaller effects in patients who were omalizumab-intolerant/incomplete responders” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remibrutinib, a Bruton's tyrosine kinase inhibitor, has shown efficacy in reducing disease symptoms in patients remaining symptomatic despite treatment with sgH1-AH in clinical trials, without a notable drop in efficacy in biologic-experienced patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cyclosporine: candidate predictors of response, systematic review
“Our systematic review showed that positive autologous serum skin test results, positive baseline basophil histamine release assays, positive baseline basophil activation test responses, elevated baseline plasma D-dimer levels, elevated baseline serum interleukin (IL)-2, IL-5, and tumor necrosis factor-alpha (TNF-α) levels, and low baseline serum IgE levels might assist in predicting favorable CsA responses in CSU patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparative network meta-analysis: consistency across age groups and baseline severity
Sex: poorer urticaria control in women across treatment categories, CURE registry
“Specifically, a higher number of females had UCT < 12 compared to males when treated with standard-dose second-generation anti-histamines (sgAH; 70.5% vs. 66.9%, p = 0.02), high-dose sgAH (76.5% vs. 73.9%, p = 0.02), omalizumab (53% vs. 44.5%, p = 0.03) and cyclosporine (81% vs. 71.4%, p = 0.02; Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote